HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Phase III clinical evaluation of gadoteridol injection: experience in pediatric neuro-oncologic MR imaging.

Abstract
Twenty-two pediatric patients with known CNS neoplasms underwent magnetic resonance (MR) imaging before and after intravenous injection of 0.1 mmol/kg gadoteridol injection as part of a Phase IIIB open label multicenter clinical trial. Intravenous administration of this neutral, nonionic contrast agent was found to be safe in children. No clinically relevant changes in vital signs or laboratory values (including complete blood count, blood chemistry, serum electrolytes, thyroid and metabolic panel and clotting function) were attributed to the administration of gadoteridol injection. There were no systemic complaints. The imaging characteristics of gadoteridol in pediatric CNS disease appeared similar to those of gadopentetate dimeglumine. Contrast enhancement was present in 17 of 22 patients (77%). The administration of gadoteridol injection provided additional clinically relevant information including improved visualization and delineation of the primary lesion, detection of additional lesions, determination of tumor recurrence and narrowing the list of differential considerations in all 17 enhancing studies as well as in 2 of 5 studies without signal intensity enhancement. The very low toxicity, inherent to this nonionic low osmolal paramagnetic contrast formulation may allow administration of increased doses at increased infusion rates for an increased number of indications with improved sensitivity.
AuthorsJ F Debatin, S N Nadel, L Gray, H S Friedman, P Trotter, B Hockenberger, W J Oakes
JournalPediatric radiology (Pediatr Radiol) Vol. 22 Issue 2 Pg. 93-8 ( 1992) ISSN: 0301-0449 [Print] Germany
PMID1501959 (Publication Type: Clinical Trial, Journal Article, Multicenter Study)
Chemical References
  • Contrast Media
  • Heterocyclic Compounds
  • Organometallic Compounds
  • gadoteridol
  • Gadolinium
Topics
  • Adolescent
  • Central Nervous System Neoplasms (diagnosis)
  • Child
  • Child, Preschool
  • Contrast Media (administration & dosage, adverse effects)
  • Female
  • Gadolinium
  • Heterocyclic Compounds (administration & dosage, adverse effects)
  • Humans
  • Infant
  • Injections, Intravenous
  • Magnetic Resonance Imaging (methods)
  • Male
  • Organometallic Compounds (administration & dosage, adverse effects)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: